Velocity Clinical Research, Hallandale Beach

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Diabetic neuropathy4 trials
• Migraine4 trials
• Alzheimer disease2 trials
• Schizophrenia2 trials
• Bipolar disorder1 trial
• Depression1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Liver cirrhosis1 trial
• Obesity1 trial
• Type 2 diabetes1 trial

Phase

• Phase 314 trials
• Phase 22 trials
• Phase 41 trial

Status

• Recruiting7 trials
• Completed6 trials
• Active, not recruiting4 trials
• Terminated1 trial

Lead sponsor

• Vertex Pharmaceuticals Incorporated4 trials
• Cassava Sciences, Inc.2 trials
• Ipsen2 trials
• Bristol-Myers Squibb1 trial
• Eli Lilly and Company1 trial
• and 8 more

Running trials

• Recruiting

  A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07816367· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Beth Safirstein

• Recruiting

  A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

  NCT07767903· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

  Contact: Safirstein (principal investigator)

• Recruiting

  Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

  NCT07565428· Phase 3· Minerva Neurosciences· Source

  Contact: Chief Operating Officer

• Recruiting

  Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

  NCT07231419· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  NCT06929273· Phase 3· Bristol-Myers Squibb· Source

  Contact: Beth Safirstein, Site 0133

• Recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

  NCT06641466· Phase 3· Pfizer· Source

• Active, not recruiting

  Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

  NCT06696443· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

  NCT06628908· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

  NCT06267391· Endogenex, Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

  NCT06047444· Phase 3· Ipsen· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

  NCT06047457· Phase 3· Ipsen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Diabetic neuropathy2 recruiting
• Migraine2 recruiting
• Bipolar disorder1 recruiting
• Schizophrenia1 recruiting

Closed trials

• Recruiting

  Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

  NCT06619860· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

  NCT05822830· Phase 3· Eli Lilly and Company· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

  NCT04599855· Phase 4· Janssen Research & Development, LLC· Source